Genetic manipulation of exosomes, virus-sized particles released by all cells, may offer a new therapeutic approach to treating pancreatic cancer, according to a study at The University of Texas MD Anderson Cancer Center.
Houston Methodist is launching the Center for Immunotherapy Research under the leadership of Shu-Hsia Chen, Ph.D., a cancer immunotherapy researcher recruited from Icahn School of Medicine at Mount Sinai.
The University of Texas MD Anderson Cancer Center and Hitachi Healthcare Americas Corporation, have today announced that they have entered into an agreement to collaborate on research for a unique randomized clinical trial comparing the outcomes and side-effects of intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of oropharyngeal cancer of the head and neck.
The blend of bacteria in the digestive tract of metastatic melanoma patients is associated with disease progression or delay in patients treated with immunotherapy, researchers at The University of Texas MD Anderson Cancer Center report at the 2017 annual meeting of the American Society of Clinical Oncology.
Researchers from Houston Methodist and Italian super sports car maker Automobili Lamborghini are working together on new carbon fiber materials for implantable devices used in therapeutic drug delivery and orthopedics.
A combination regimen of two immunotherapies and another of two targeted therapies each significantly shrank metastatic brain tumors in at least 50 percent of patients in separate multi-center clinical trials presented today at the 2017 ASCO Annual Meeting by principal investigators from The University of Texas MD Anderson Cancer Center.
A study at The University of Texas MD Anderson Cancer Center has shown promise for effective treatment of therapy-resistant cancers caused by a mutation of the RAS gene found in many cancers. The pre-clinical study combined therapies targeting the inhibitors polyADP ribose polymerase (PARP) and mitogen-activated protein kinase (MEK). The findings were published this week in Science Translational Medicine.
For more than two months, Kim O’Neill, 61, spent nearly every night lying in bed, staring at the ceiling and wondering if she was going to die in her sleep. Her heart was beating so loudly in her chest she thought it might explode. During the day, she would struggle to walk up a flight of stairs to the second floor of her home and would run out of breath in the middle of a conversation with her husband. A typically active and positive person, O’Neill was terrified that this was her new normal.
Everything changed in December 2016 when she met Ramesh Hariharan, M.D., a cardiac electrophysiologist with McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth) and Memorial Hermann The Woodlands Hospital.
All cancer tumors have one thing in common – they must feed themselves to grow and spread, a difficult feat since they are usually in a tumor microenvironment with limited nutrients and oxygen. A study at The University of Texas MD Anderson Cancer Center has revealed new details about how an enzyme called acetyl-CoA synthetase 2 (ACSS2) allows brain tumors to grow despite their harsh surroundings.
With the opening of the new UT Physicians Community Health & Wellness Center – Jensen, children and adults living in north Houston can receive high-quality primary care and medical screenings at a multispecialty clinic. It opened May 16.
A clinical trial to evaluate the safety and efficacy of a stem cell product injected directly into the brain to treat chronic motor deficits from ischemic stroke has begun at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth).
Genetic alterations that can be modulated by stress have been identified in children at high risk for bipolar disorder, according to a recently published study by researchers at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth). Results appeared in Translational Psychiatry, a Nature Publishing Group journal.
A clinical trial of a drug that researchers hope can prevent or delay the onset of epilepsy in children with tuberous sclerosis has begun at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth).
The University of Texas MD Anderson Cancer Center named eight innovative researchers to the second annual class of Andrew Sabin Family Fellows at a luncheon today attended by Andrew Sabin, of East Hampton, New York, and representatives of the Andrew Sabin Family Foundation. The Andrew Sabin Family Fellowship Program provides $100,000 in funding per fellow over two years through a $30 million endowed gift to encourage research creativity, independent thinking and high-impact cancer research.
Hulin Wu, Ph.D., has been selected as the new chair of the Department of Biostatistics at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health.
Cold weather increases the risk of mortality in Texas residents, according to researchers at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health. The findings were recently published in the journal Environmental Pollution.
The University of Texas MD Anderson Children’s Cancer Hospital joins Houston restaurants and businesses to host its second annual Prom Party Palooza, a prom for teen cancer patients and their families. The glamorous night takes place at MD Anderson on Saturday, April 29 from 6 to 9 p.m.
To help train youth to become educators and advocates for tobacco policy change, The University of Texas Health Science Center at Houston (UTHealth) School of Public Health in El Paso is partnering with El Paso Independent School District high schools to create an innovative new program.
When little Aiden Sandoval was born, lactation consultant Delia Peña was in the birthing suite ready to place him against his mother’s bare chest. It’s a vital part of the delivery of babies at Harris Health System and one that studies show can make a tremendous impact on a newborn’s development.
Select breast cancer patients who achieved pathologic complete response (pCR) after chemotherapy may be able to avoid follow-up breast and lymph node, or axillary, surgery, according to new findings from researchers at The University of Texas MD Anderson Cancer Center. The study, published today in JAMA Surgery, identifies the exceptional responders who are at lowest risk for local metastases and thereby are candidates for less invasive treatment options.
The University of Texas MD Anderson Cancer Center and Lion Biotechnologies, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced a multi-year strategic alliance agreement involving multi-arm clinical trials to evaluate the safety and efficacy of TIL therapy in ovarian, various sarcomas, and pancreatic cancers.
Specific strains of bacteria in the gut are significantly associated with colorectal cancer, according to a new study by researchers at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health.
Harris Health System recognized its longest tenured board of trustee-more than 31 years of service-by naming the Harris Health administration building in his honor. Harris Health is the public healthcare system in Houston and Harris County, Texas.
Simon Barquera, M.D., Ph.D., director of the Nutrition Policy Research Division at the National Institute of Public Health of Mexico, was honored yesterday at the 11th annual Michael & Susan Dell Lectureship in Child Health.
Research led by a Houston Methodist gastroenterologist shows that patients who have inflammatory bowel disease (IBD) for more than two decades have a higher risk of developing nonalcoholic fatty liver disease (NAFLD).
A Houston Methodist-led research team showed that the systemic administration of nanoparticles triggers an inflammatory response because of blood components accumulating on their surface.
Oncora Medical, a precision radiation oncology software company, and The University of Texas MD Anderson Cancer Center, today announced a strategic alliance focusing on building the next generation of precision medicine software for radiation oncology.
An Innovative Research Grant from Stand Up to Cancer will help a University of Texas MD Anderson Cancer Center physician scientist and her team understand how the bacteria in the digestive tracts of melanoma patients affects their response to a common immunotherapy drug.
Flavored e-cigarettes and e-cigarette marketing could be increasing e-cigarette use among youth and young adults, according to researchers from the Michael & Susan Dell Center for Healthy Living at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health in Austin. These findings are part of a series of papers by UTHealth researchers that were published today in the journal Tobacco Regulatory Science.
Capturing high-resolution images of a patient's eye and retina are vital to ensure good vision for people with diabetes. It takes patience and attention to detail for ophthalmology technicians to produce high-quality images that trained experts at Harris Health System can use to spot vision loss/problems.
Immunologic changes observed in an early study of patients with metastatic renal cell carcinoma (MRCC) raised the possibility for a larger clinical study of combination immunotherapy, according to findings reported by researchers at The University of Texas MD Anderson Cancer Center.
Susan Wootton, M.D., associate professor of pediatric infectious diseases at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth), will lead a project to increase low vaccination rates among pre-kindergarten and kindergarten students in the Houston Independent School District (HISD).
A protein known as arginine methyltransferase 1 (PRMT1) may be a potential therapeutic target for pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, and one of the most deadliest with a less than 10 percent, five-year survival rate. PRMT1 is involved in a number of genetic processes including gene transcription, DNA repair and signaling.
A study of racial disparities in health-related quality of life of colorectal cancer patients revealed among several findings, that Hispanics and blacks had a higher burden of poor health-related quality-of-life (HR-QoL) than white patients and that poor HR-QoL resulted in shorter median survival. Yet Hispanics had an average survival time of 85.4 months as compared to blacks at 47.8 months and whites at 43.2 months.
Prostate cancer, notoriously resistant to immunotherapy due to its immunologically cool nature, triggers two pathways to chill an immune attack after one immunotherapy drug fires up the immune system, researchers at The University of Texas MD Anderson Cancer Center report in Nature Medicine.
No graduate nursing program in the Lone Star State is ranked higher than The University of Texas Health Science Center at Houston (UTHealth) School of Nursing, according to the just-released 2018 edition of the influential Best Graduate Schools guide.
Researchers at The University of Texas MD Anderson Cancer Center developed a novel chimeric mouse model to test the combination therapy using immune checkpoint blockades with therapies targeting myeloid-derived suppressor cells (MDSCs).
The effect of multipotent adult progenitor stem cells on stroke recovery were the focus of two recently published papers that include researchers at the Institute for Stroke and Cerebrovascular Disease at The University of Texas Health Science Center at Houston (UTHealth).
An advanced form of image-guided radiation therapy, known as intensity modulated proton therapy (IMPT), has shown early promise for the treatment of recurrent lung cancer, according to new research from The University of Texas MD Anderson Cancer Center.
Medtronic plc (NYSE: MDT) today unveiled first-ever clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial, which was presented at the American College of Cardiology (ACC) 66th Annual Scientific Session and published simultaneously in The New England Journal of Medicine (NEJM) (1).
As an institution devoted to eliminating cancer, The University of Texas MD Anderson Cancer Center proudly supports the mission of Kick Butts Day to prevent tobacco use in our nation’s children. Organized by the Campaign for Tobacco-Free Kids (CTFK), Kick Butts Day is a national day of awareness focused on educating and empowering youth to choose tobacco-free lifestyles. Through several evidence-based programs, MD Anderson has committed to educating youth about the dangers of tobacco use and its effects on their future health.
Frozen and freeze-dried products for Fecal Microbiota Transplantation (FMT) are nearly as effective as fresh product at treating patients with Clostridium difficile (C-diff) infection, according to researchers at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health and Kelsey Research Foundation.
The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded $1.5 million to researchers at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health for a project designed to increase human papillomavirus (HPV) vaccine rates among minority youth in medically underserved areas across Houston.
Anne Clutterbuck, former Houston City Councilmember, has been elected chair of the Harris Health System Board of Trustees, the governing body of the public healthcare system in Harris County. Harris Health has served the community of Houston/Harris County for more than 50 years.
A new automated microbiology laboratory that grows, incubates and identifies bacteria in minutes won Innovation of the Year at Harris Health System’s Innovation Summit, a celebration of the staff suggestion program to improve patient care, environments and organizational processes.
A type of functional brain training known as neurofeedback shows promise in reducing symptoms of chemotherapy-induced nerve damage, or neuropathy, in cancer survivors, according to a study by researchers at The University of Texas MD Anderson Cancer Center. The pilot study, published in the journal Cancer, is the largest, to date, to determine the benefits of neurofeedback in cancer survivors.
The Robert Wood Johnson Foundation (RWJF) has awarded a three-year, $2.4 million grant to The University of Texas Health Science Center at Houston (UTHealth) to create the Healthy Cities Research Hub: Exploring Drivers of Diabetes and Other Chronic Diseases.
The University of Texas Health Science Center at Houston (UTHealth), in collaboration with the Human Genome Sequencing Center at Baylor College of Medicine (HGSC), is a participant in a $500 million program of the National Heart, Lung, and Blood Institute (NHLBI) Trans-Omics for Precision Medicine (TOPMed) program to bring whole genome sequencing and other “omic” technologies that monitor the expression of the genome in response to the environment to the forefront of clinical research.
A Phase III clinical trial involving 101 centers in 21 countries revealed the monoclonal antibody blinatumomab to be more effective than standard chemotherapy for treatment of advanced acute lymphoblastic leukemia (ALL). Study findings were published in the March 1 online issue of the New England Journal of Medicine.